The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical outcomes of gemcitabine plus nab-paclitaxel (GnP) in initially diagnosed locally advanced pancreatic cancer.
 
Yusuke Hashimoto
No Relationships to Disclose
 
Hideaki Takahashi
Honoraria - Bayer; Taiho Pharmaceutical
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Izumi Ohno
No Relationships to Disclose
 
Hiroshi Imaoka
No Relationships to Disclose
 
Mitsuhito Sasaki
No Relationships to Disclose
 
Kumiko Umemoto
No Relationships to Disclose
 
Kazuo Watanabe
No Relationships to Disclose
 
Gen Kimura
No Relationships to Disclose
 
Shuichi Mitsunaga
No Relationships to Disclose
 
Masafumi Ikeda
Honoraria - Abbott Japan; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; Nobelpharma; Novartis; Otsuka; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Eisai; Kyowa Hakko Kirin; NanoCarrier; Novartis; Shire
Research Funding - ASLAN Pharmaceuticals; AstraZeneca; Baxter; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Eisai; Kowa; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; NanoCarrier; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Pharmaceutical; Zeria Pharmaceutical